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Elliott M. Antman, MD, FACC,* Stephen D. Wiviott, MD,* Sabina A. Murphy, MPH,*
Juri Voitk, MD, FACC,† Yonathan Hasin, MD,‡ Petr Widimsky, MD, DRSC,§
Harish Chandna, MBBS, FACC,¶ William Macias, MD, PHD, Carolyn H. McCabe, BS,*
Eugene Braunwald, MD, MACC*
Boston, Massachusetts; Tallinn, Estonia; Poriya, Israel; Prague, Czech Republic; Victoria, Texas;
and Indianapolis, Indiana
Objectives We evaluated the relative contributions of the loading and maintenance doses of prasugrel on events in a
TRITON–TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with
Prasugrel–Thrombolysis In Myocardial Infarction) analysis.
Background Prasugrel is superior to clopidogrel in preventing ischemic events in patients with an acute coronary syndrome who
are undergoing percutaneous coronary intervention, but it is associated with an increased risk of major bleeding.
Methods Landmark analyses for efficacy, safety, and net clinical benefit were performed from randomization to day 3 and
from day 3 to the end of the trial.
Results Significant reductions in ischemic events, including myocardial infarction, stent thrombosis, and urgent target
vessel revascularization, were observed with the use of prasugrel both during the first 3 days and from 3 days to
the end of the trial. Thrombolysis In Myocardial Infarction major non–coronary artery bypass graft bleeding was
similar to clopidogrel during the first 3 days but was significantly greater with the use of prasugrel from 3 days
to the end of the study. Net clinical benefit significantly favored prasugrel both early and late in the trial.
Conclusions Both the loading dose and maintenance dose of prasugrel were superior to clopidogrel for the reduction of ischemic
events. This result emphasizes the importance of maintaining high levels of inhibition of platelet aggregation via
P2Y12 receptor inhibition, not only for the prevention of periprocedural ischemic events but also during long-term
follow-up. The excess major bleeding observed with the use of prasugrel occurred predominantly during the mainte-
nance phase. Approaches to reduce the relative excess of bleeding with prasugrel should focus on the maintenance
dose (e.g., reduction in maintenance dose in previously reported high-risk subgroups, such as the elderly and those
patients with low body weight). (A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are
to Undergo Percutaneous Coronary Intervention; NCT00097591) (J Am Coll Cardiol 2008;51:2028–33) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.002n
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ohe use of dual antiplatelet therapy with aspirin and a
hienopyridine is an essential aspect of the supportive pharma-
ologic regimen administered to patients with an acute coro-
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ccepted April 7, 2008.ary syndrome (ACS) who are undergoing percutaneous cor-
nary intervention (PCI) (1–3). To achieve levels of the active
etabolite sufficient to inhibit the P2Y12 receptor around the
ime of PCI, the thienopyridine dosing strategy begins with a
oading dose (1–3) followed by long-term therapy with a daily
aintenance dose that should not be discontinued prematurely
o avoid ischemic complications (4). Despite its established
ffectiveness as the thienopyridine element of the dual anti-
latelet regimen, clopidogrel has several limitations, including
nly a modest antiplatelet effect with a delayed onset of action
nd considerable interpatient variability (5–7). The active
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May 27, 2008:2028–33 Early and Late Benefits of Prasugreletabolite is generated more efficiently after the administra-
ion of the novel thienopyridine prasugrel, allowing construc-
ion of a dosing regimen that consistently yields significantly
reater levels of inhibition of platelet aggregation (IPA) after
oth the loading dose and the maintenance dose (8).
The TRITON–TIMI 38 (TRial to Assess Improvement in
herapeutic Outcomes by Optimizing Platelet InhibitioN
ith Prasugrel–Thrombolysis In Myocardial Infarction) trial
emonstrated that a prasugrel regimen of a loading dose of 60
g and daily maintenance dose of 10 mg was significantly
uperior to the standard regimen of clopidogrel (300-mg
oading dose and 75-mg daily maintenance dose) in preventing
he composite end point of death from cardiovascular causes,
onfatal myocardial infarction (MI), or nonfatal stroke during
median duration of therapy of 15 months (9). The reduction
n the primary end point was driven by a significant 24%
eduction in MI; significant reductions of 34% and 52% in
rgent target vessel revascularization and stent thrombosis,
espectively, also occurred (9). These benefits of prasugrel over
lopidogrel in preventing ischemic events were achieved at the
ost of an increased rate of Thrombolysis In Myocardial
nfarction (TIMI) major noncoronary artery bypass grafting
CABG)–related bleeding. Net clinical benefit (death from any
ause, nonfatal MI, nonfatal stroke, and nonfatal TIMI major
on–CABG-related bleeding) significantly favored the use of
rasugrel over the course of the trial (9).
Both the loading and maintenance doses of prasugrel stud-
ed in TRITON–TIMI 38 yield greater levels of IPA than a
tandard dose of clopidogrel. Therefore, it is important to
ssess their relative contributions to the benefits of prasugrel in
he reduction of ischemic events and excess bleeding observed
n the trial and to examine the effects of prasugrel on the net
linical benefit of these doses. In the present paper, we explored
he impact of the loading and maintenance doses of prasugrel
ver a range of individual pre-specified efficacy end points. The
urrent analysis also provides us the opportunity to assess the
iming of prasugrel’s impact on the risk of major bleeding and
et clinical benefit.
ethods
tudy protocol. As described previously, a total of 13,608
atients with an ACS (both unstable angina/non–ST-
egment myocardial infarction [UA/NSTEMI] and ST-
egment myocardial infarction [STEMI]) were randomized
n TRITON–TIMI 38 (9). Because the objective was to
ompare the use of prasugrel with clopidogrel in patients
ith ACS who were undergoing PCI, the coronary anatomy
f all UA/NSTEMI and post-STEMI patients had to be
nown to be suitable for PCI before randomization (10).
If the coronary anatomy was previously known or primary
CI for STEMI was planned, pre-treatment with study
rug was allowed for up to 24 h before PCI. Randomization
as to occur before the onset of PCI, and blinded study
rug administration was to be administered as soon as
ossible after randomization. Decisions regarding the bhoice of vessels for PCI, the
evices used, and the adjunctive
edications were at the discre-
ion of the treating physician.
uring the maintenance phase,
atients were to receive a daily
ose of aspirin of 75 to 162 mg
nd the blinded study drug. After
ospital discharge, follow-up vis-
ts were conducted at 30-day,
0-day, and at 3-month intervals
hereafter for a minimum of 6
onths and maximum of 15
onths (10).
nd points. Details of the def-
nitions of the end points are
escribed in previous reports
9,10). In the analyses reported
erein, we used the same defini-
ions of MI, urgent target vessel revascularization, stent
hrombosis (Academic Research Consortium definite or
robable) (11), TIMI major non–CABG-associated bleed-
ng, and net clinical benefit as in the main trial. All end
oints used in the analyses in this report were adjudicated by
embers of an independent clinical events committee that
as blinded to the treatment assignment.
The investigators had free and complete access to the data
sed for these analyses. Members of the TIMI Study Group
ndependently conducted the analyses, wrote the paper
sing a copy of the raw database for the main trial, and take
ull responsibility for this report. All analyses were per-
ormed with the use of STATA/SE 9.2 (STATA Corp.,
ollege Station, Texas).
tatistical analyses. All efficacy analyses were performed
ccording to the intention-to-treat principle. Safety analyses
ere conducted in the cohort of patients who received at
east 1 dose of the study drug. The time to first event in the
treatment groups was analyzed using Kaplan-Meier curves
nd compared using the log-rank test.
Landmark analyses were performed with the pre-specified
indows of randomization to day 3 and from day 3 to the
nd of the trial (9). The landmark method of survival
nalysis uses a fixed time after the initiation of treatment to
ssess the response in treatment groups (12,13). Landmark
nalysis specifies the cutpoint in time after start of treatment
ithout regard to patient response to therapy. Of impor-
ance, this specification provides us the opportunity to
erform a separate statistical test to determine whether the
esponse to treatment after the landmark time is different in
he treatment groups (12,13). It should be noted that a
imitation of landmark analysis is that the original effects of
andomization at entry into the trial are no longer present
ecause of deaths or dropouts before the time of the
andmark cutpoint. There is a precedent for landmark
nalyses in both oncology and cardiology (12,13), but
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CABG  coronary artery
bypass graft
HR  hazard ratio
IPA  inhibition of platelet
aggregation
MI  myocardial infarction
PCI  percutaneous
coronary intervention
TIMI  Thrombolysis In
Myocardial Infarction
UA/NSTEMI  unstable
angina/non–ST-segment
myocardial infarctionecause of the observational nature of landmark methodology,
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Early and Late Benefits of Prasugrel May 27, 2008:2028–33he findings should be interpreted in the context of cumulative
urvival analyses from randomization to the end of the study
as reported previously for TRITON–TIMI 38) (9).
The rationale for selection of the day 3 cutpoint for the
andmark analyses was to separate, as much as possible,
vents that could be attributed to the loading dose (peripro-
edural events) and maintenance dose (events during long-
erm follow-up) phases of the study. On the basis of a
reviously reported pharmacodynamic and pharmacokinetic
tudy of prasugrel and clopidogrel, a stable level of IPA
ttributable to the maintenance dose was evident by day 3
nd was also independent of the loading dose of clopidogrel
dministered (14). When performing the landmark analyses
rom day 3 to the end of the trial, we ascertained that the
umber of patients at risk included all patients who were
live, regardless of whether a nonfatal event had occurred
uring the first 3 days, and had not withdrawn consent for
ollow-up. We considered p  0.05 to indicate statistical
ignificance. Hazard ratios (HRs) and associated 95% con-
dence intervals were calculated with a Cox proportional
azards survival model to evaluate the relative treatment
ffect. For subgroup analyses, an interaction term between
he randomized treatment and subgroup was entered into a
ox model.
esults
total of 13,608 patients were randomized and formed the
ntention-to-treat cohort. Of these, 99% underwent PCI
nd 94% received at least 1 stent. The safety cohort
onsisted of 13,457 patients who had received at least 1 dose
f study drug.
fficacy. The 3-day landmark analyses for the ischemic
vents of MI, stent thrombosis, and urgent target vessel
evascularization are shown in Figure 1. A consistent
attern of significant reductions in each of these end points
ith prasugrel was found both during the first 3 days and
rom 3 days to the end of the trial. The reduction in the HR
or MI in favor of the prasugrel group was 19% in the first
days and 31% from 3 days to the end of the trial.
Reductions in the HR were observed with prasugrel for
tent thrombosis (51% reduction by 3 days [p  0.006] and
5% reduction from 3 days to the end of the trial [p 
.0001]) and urgent target vessel revascularization (34%
eduction by 3 days [p  0.047] and 35% reduction from 3
ays to the end of the trial [p  0.0003]). Of the 300
pisodes of urgent target vessel revascularization that oc-
urred from 3 days to the end of the trial, glycoprotein
Ib/IIIa inhibitors were used in 57 (19.0%) cases (14
11.8%] with prasugrel and 43 [23.8%] with clopidogrel;
 0.01).
During the maintenance phase, the absolute risk differ-
nces with prasugrel were 1.39%, 0.94%, and 1.03% for the
nd points of MI, stent thrombosis, and urgent target vessel 3evascularization, respectively. Inspection of the event
urves shows a progressive widening of the differences
etween the 2 treatment groups for stent thrombosis and
rgent target vessel revascularization during the first 3
ays and for all 3 efficacy end points from 3 days to the
nd of the trial.
Interaction tests showed no significant effect of stent
ype at the index PCI (bare-metal stents vs. drug-eluting
tents) on the treatment benefits of prasugrel in prevent-
ng urgent target vessel revascularization during the first
days (Pinteraction  0.35) or from 3 days to the end of the
rial (Pinteraction  0.17). Similarly, there was no effect of
tent type on prevention of stent thrombosis with pra-
ugrel during the first 3 days (Pinteraction  0.16) or from
Figure 1 Landmark Analyses of Efficacy
Landmark analyses (survival method) of the Kaplan-Meier estimates of myocar-
dial infarction (MI), stent thrombosis, and urgent target vessel revascularization
(uTVR) during the first 3 days after randomization (left side of each panel) and
from 3 days to the end of the study (right side of each panel) are shown for
the prasugrel and clopidogrel groups. There were significant reductions in the
hazard ratio (HR) for each end point both during the first 3 days and from 3
days to the end of the study that were consistent with independent superiority
of the loading and maintenance doses of prasugrel compared with clopidogrel.days to the end of the trial (Pinteraction  0.64).
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May 27, 2008:2028–33 Early and Late Benefits of Prasugrelafety and net clinical benefit. The 3-day landmark anal-
ses for TIMI major non-CABG bleeding and net clinical
enefit are shown in Figure 2. Through the first 3 days, the
ate of TIMI major non-CABG bleeding was numerically
reater with the use of prasugrel (0.74%) compared with
lopidogrel (0.61%), but this 0.13% absolute risk increase
id not achieve statistical significance. From 3 days to the
nd of the trial, the rate of major bleeding was significantly
reater with the use of prasugrel compared with clopidogrel
39% increase in the HR and 0.48% absolute risk increase).
n interaction test of the treatment effect of prasugrel on
ajor bleeding in the 0- to 3-day and 3-day periods was
ot significant (Pinteraction  0.62). Inspection of the event
urves for major bleeding does not suggest progressive
idening of the differences between the treatment groups
or the first 3 days, but there does appear to be a steeper
ncrease in the rate of bleeding events over time with
rasugrel compared with clopidogrel from 3 days to the end
f the study. The net clinical benefit composite end point
as significantly in favor of prasugrel both during the first 3
ays and from 3 days to the end of the study. The reduction
Figure 2 Landmark Analyses of
Safety and Net Clinical Benefit
Landmark analyses (survival method) of the Kaplan-Meier estimates of Throm-
bolysis In Myocardial Infarction major noncoronary artery bypass grafting bleed-
ing and net clinical benefit during the first 3 days after randomization (left side
of each panel) and from 3 days to the end of the study (right side of each
panel) are shown for the prasugrel and clopidogrel groups. There was no signif-
icant increase in major bleeding with prasugrel during the first 3 days, but
there was a significant increase from 3 days to the end of the study. Net clini-
cal benefit favored prasugrel during both the early and late phases of the
study. HR  hazard ratio.1n the HR was 15% and 13% during the 2 time periods,
espectively.
iscussion
he findings of the present analysis add considerably to the
nderstanding of the profile of the clinical response to
rasugrel compared with clopidogrel in patients with an
CS undergoing PCI. We previously reported in a land-
ark analysis that treatment with prasugrel was associated
ith significant reductions in the primary end point by the
rst pre-specified time point, 3 days as well as from 3 days
o the end of the trial (9). The exploratory landmark analyses
eported here show that there is a consistent significant benefit
f prasugrel across multiple individual efficacy end points both
arly (loading dose phase) and late (maintenance dose phase)
fter randomization in TRITON–TIMI 38. There is inter-
al consistency in that prasugrel prevented a range of
schemic events that are related to platelet activation and
ggregation. The benefits of prasugrel in preventing isch-
mic events not only emerged rapidly (avoidance of peripro-
edural events) but continued to accrue during long-term
reatment (avoidance of recurrent events). These efficacy
bservations support the concept that prasugrel is superior
o the standard dose of clopidogrel as the thienopyridine
oth for acute pharmacologic support of PCI as well during
he chronic phase of management after PCI (9).
The chemical structure of prasugrel leads to the more
fficient conversion of the prodrug to its active metabolite
ith less dependence on specific cytochrome P-450 en-
ymes (8). As reported in studies of platelet function, there
s a very rapid onset of substantial levels of IPA achievable
ith prasugrel, levels that are significantly greater than can
e achieved by standard dosing with clopidogrel (8). The
reater prevention of the periprocedural events of MI, stent
hrombosis, and urgent target vessel revascularization dur-
ng the first 3 days with prasugrel compared with standard
osing with clopidogrel is therefore likely the result of rapid
ttainment of much greater levels of IPA. The speed of
nset of prasugrel’s antiplatelet effect offers the clinician the
pportunity to determine that the coronary anatomy is
uitable for PCI before committing to irreversible P2Y12
nhibition. This strategy overcomes the liability of a com-
only used strategy of pre-treating with clopidogrel before
CI, which exposes patients to substantially increased risks
f perioperative bleeding if urgent CABG surgery is re-
uired as well as non–CABG-related bleeding (15–17).
The 10-mg maintenance dose of prasugrel also produces
ignificantly greater levels of IPA than the standard 75-mg
aintenance dose of clopidogrel (8). Our landmark analyses
nd the shape of the event curves from day 3 through the
nd of the trial are consistent with an independent benefit of
rolonged treatment with prasugrel compared with clopi-
ogrel. The more consistent and greater levels of IPA with
0 mg of prasugrel reported in platelet function studies
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Early and Late Benefits of Prasugrel May 27, 2008:2028–33ranslated into prevention of more ischemic events in
atients during the maintenance phase of therapy after PCI
8). Especially notable among these results was the large
reatment effect on stent thrombosis, an infrequent but
erious and often fatal complication after PCI (18).
The landmark analyses reported herein provide one
mportant step in linking the greater levels of IPA achieved
ith the loading and maintenance doses of prasugrel com-
ared with standard doses of clopidogrel in preventing early
nd late ischemic events. Of note, significantly greater levels
f IPA were achieved with the loading and maintenance
oses of prasugrel studied in the TRITON–TIMI 38 trial
ven when compared with higher-than-standard doses of
lopidogrel (600-mg loading dose and 150-mg maintenance
ose) in the PRINCIPLE–TIMI 44 (Prasugrel in Compar-
son to Clopidogrel for Inhibition of Platelet Activation and
ggregation–Thrombolysis In Myocardial Infarction) trial
19). Furthermore, the ISAR-REACT 2 (Intracoronary
tenting and Antithrombotic Regimen: Rapid Early Action
or Coronary Treatment) investigators reported that even
re-treatment with 600 mg of clopidogrel before PCI was
nadequate antiplatelet therapy in patients with NSTEMI
nd additional treatment with abciximab was required to
imit ischemic events (20).
Although formal interaction testing of the impact of
rasugrel on early and late bleeding events was not signifi-
ant, it should be noted that such interaction tests are
elatively weak and may fail to detect important quantitative
ifferences if the number of events is small, as is the case for
leeding within the first 3 days. On the basis of the absolute
nd relative event rates, our landmark analysis suggests the
eriod from 3 days to the end of the trial as the major risk
eriod for excess bleeding with prasugrel. As noted in
everal Food and Drug Administration guidance docu-
ents, the relationship between exposure and response to a
rug may place certain subsets of the population at increased
isk of toxicity (21,22). This relationship can be assessed
hrough population-pharmacokinetic studies embedded
ithin a large trial (21). Modeling can be used to predict
odified dosing regimens for special populations to main-
ain efficacy and reduce risk (21). We previously identified
everal high-risk patient subsets of the TRITON–TIMI 38
rial population for whom net clinical benefit analyses were
eutral (i.e., reduction in primary end point events was
ffset by an increase in bleeding events) and who may be
andidates for a reduced maintenance dose (9). These
ubsets include individuals 75 years of age and those
eighing 60 kg (together representing approximately 16%
f the patients studied in TRITON–TIMI 38). Although
he elderly and low body weight patients tended to have
ewer primary end point events with prasugrel versus clopi-
ogrel, this result was offset by a greater rate of major
leeding, resulting in a neutral net clinical benefit end point
9). Our landmark analyses of major bleeding suggest that
he focus of ongoing population-pharmacokinetic analyses
n TRITON–TIMI 38 should be on modeling to identify a
1uitable reduction of the maintenance dose in such high-risk
roups.
linical implications. The superiority of both the loading
ose and maintenance dose of prasugrel compared with the
tandard dose of clopidogrel emphasizes the benefits of high
evels of IPA via P2Y12 receptor inhibition not only for
revention of periprocedural ischemic events but also during
ong-term follow-up. The greatest risk of the more aggres-
ive antiplatelet regimen with prasugrel is excess major
leeding, especially during chronic therapy. Efforts to min-
mize the risk of excess bleeding with prasugrel are needed.
logical approach in this regard is reduction of the
aintenance dose (e.g., 5 mg) in previously reported high-
isk subgroups (elderly, low body weight) (9).
eprint requests and correspondence: Dr. Elliott M. Antman,
ardiovascular Division, Brigham and Women’s Hospital, TIMI
tudy Group, 350 Longwood Avenue, 1st Floor, Boston, Massa-
husetts 02115. E-mail: eantman@rics.bwh.harvard.edu.
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